A Phase I, Randomized, Crossover Study to Compare the Pharmacokinetics and Daefty of rAHF-PFM Reconstituted in 2mL versus 5mL in Previously Treated Severe Hemophilia A Patients

Grants and Contracts Details

StatusFinished
Effective start/end date11/11/0812/31/09

Funding

  • Baxter Healthcare Co: $9,642.00